Innate Immunity in Ozone-induced Airway Inflammation in COPD (NCT04669743)
🩺 Plain-English Summary (8th-Grade Level)
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. Patients with COPD are routinely exposed to indoor and outdoor air pollution, which appears to cause escalation of their respiratory symptoms, a process called exacerbation, with resulting need to seek medical attention. This research plan proposes to evaluate the impact of lung immune cells in susceptibility to develop exacerbation through an experimental model of inhalational exposure using ambient levels of a component of air pollution (ozone) in COPD patients and longitudinal sampling of their lung immune cells.
Who can join: Review the eligibility criteria below.
Location: Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
Age range: 45 Years to 75 Years
🧪 Interventions in This Study
- Ozone exposure (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
- San Francisco VA Medical Center — San Francisco, California
- University of California, San Francisco — San Francisco, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Disease, Chronic Obstructive
- Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) — Birmingham, Alabama
- A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease — Yuma, Arizona
- Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent — Rochester, Minnesota
- Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD — Minneapolis, Minnesota
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting — Mississauga,
Explore by condition: All Pulmonary Disease, Chronic Obstructive clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.